73 results about "Cucurbitacin" patented technology

Method and pharmaceutical composition for treating anemia related symptoms. The method and formulation involve the use of one or more cucurbitacin analogs as active ingredients, for example, cucurbitacin D, which are capable of increasing hemoglobin expression, reactivating fetal or adult hemoglobin and inducing γ-globin.

The invention relates to a natural botanical vermin-proof agent, which is prepared from medicinal plants materials including datura flower, roor of sessile stemona, galangal rhizome, cucurbitacin, asaryl, clove, chestnut bark, aromatic plants, camphor, mentha and boneol.

The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a cucurbitacin using the signaling molecules in the Ras-Raf-Mek-Elk-STAT3 pathway.

Baits useful against diabroticine mature and immature beetles contain (a) an insecticide and (b) a feeding stimulant containing a cucurbitacin in a gelatin binder.

The invention discloses a new medicament application of cucurbitacins, namely an application of mixing effective monomers of cucurbitacins in medicament for treating leukaemia or an application of effective monomers of cucurbitacins to independently treating leukaemia, belonging to the technical field of medicament. The cucurbitacins with nano-mole concentration can obviously inhibit multiplication of leukaemia HL60 and K562 cells; the cucurbitacins have no cell toxic effect to human leukaemia cells in a multiplication inhibiting concentration range; and the multiplication inhibiting effect to leukaemia cells in vitro is stronger than that to solid tumour cells. Further researches suggest that the cucurbitacins with micro-mole concentration can induce apoptosis of leukaemia HL60 cells by increasing cucurbitacin concentration. Anti-tumour researches in vivo suggest that the cucurbitacins can prolong survival time of a small mouse P388 leukaemia animal model. The effective monomers of cucurbitacins in resisting leukaemia have obvious effect, low toxicity, long lasting drug administration, can be used for both chemotherapy and radiotherapy, and are promising to be further developed into the medicament for treating leukaemia.

The invention relates to a cucurbitacin soft capsule oral medicament and process for preparation, wherein the medicament includes medicinal soup and capsule shell, wherein each tablet of the soup comprises micronized cucurbitacin 0.01-10mg, dissolvent and stabilizing agent, the shell contains gelatin, plasticizing agent, preservative agent, screening agent, flavoring agent and coloring matter.

The invention belongs to the technical field of medicine and discloses novel application of Cucurbitacins, namely novel application of Cucurbitacin B, Cucurbitacin B substances, Cucurbitacin BE and a pharmaceutical composition thereof in a medicine for treating ovarian cancer and improving the quantity of leukocytes of radiotherapy patients. The Cucurbitacin can also be a cucurbitacin B monomer, an isocucurbitacin B monomer, a dihydrocucurbitacin B monomer, a cucurbitacin I monomer, and a cucurbitacin O monomer. The Cucurbitacins or pharmaceutical compositions thereof can be matched with a pharmaceutically acceptable carrier and prepared into a tablet, a capsule, a granule, powder, a plaster, an ointment, an aerosol, a suspension, a syrup, an oral liquid, and an injection, and can also beprepared into special dosage forms such as a liposome, microspheres, nanoparticles and an emulsion for cavity administration, external use, oral administration and injection. The individual administration or the combined treatment can be performed, the administration dosage of the Cucurbitacins is calculated according to the total Cucurbitacins, the dosage for healthy adults is between 0.1 and 5mg/d, the best dosage is between 0.3 and 3mg/d, and the administration is performed for 1 to 4 times.

The invention discloses a cucurbitacin nanometer agent with protein, which can be liquid agent or solid agent. The protein nanometer particle can be reserved under indoor temperature, which improves drug quality and effect. the liquid agent contains0.05-10% (W/V) protein quantity and 0.001-1% (W/V) cucurbitacin and the solid agent consists of 50-99.9% (W/V) protein and 0.001-50% (W/V) cucurbitacin.

The invention provides a preparation method of cucurbitacin compounds, which comprises the following steps: pulverizing and leaching traditional Chinese medicine muskmelon pedicel, carrying out solvent partitioning on the crude leaching sample with a methanol water solution and n-hexane, concentrating, respectively separating the concentrate with a normal-phase silica gel chromatographic column, and purifying by high performance liquid chromatography to obtain the purified cucurbitacin compounds. The cucurbitacin compounds obtained in the invention have obvious quasi-nerve growth factor activity, and can be applied to preparation of medicines for preventing senile dementia and other neurodegenerative diseases and especially to preparation of medicines for treating Alzheimer's disease and other neurodegenerative diseases. The invention develops pharmaceutical application of effective component cucurbitacin compounds. The raw material-traditional Chinese medicine muskmelon pedicel has wide sources and is convenient to take; and the preparation method is simple and can easily implement industrial production. The structural general formula is disclosed in the specification.

The invention aims at providing a cucurbitacin solid lipid nanoparticle preparation and a preparation method thereof, which can effectively solve the problems of poor stability and low quality in the prior art. The technical scheme provided by the invention is that: in the preparation, the weight ratio of cucurbitacin, lipid material and surface active agent is 0.001-30:0.01-99:0.01-50, and the sum of the cucurbitacin, the lipid material and the surface active agent accounts for 0.1-40% of the total weight of the raw materials of the nanoparticle preparation. The preparation method is as follows: heating and melting the lipid material, the surface active agent and the cucurbitacin in dark place, fully and evenly stirring; adding water for dispersing to nanoscale; filtering and cooling in the melting state. The invention has scientific and simple composition, scientific compatibility, reasonable dosage, convenient use and fine stability. The invention integrates the advantages of high physical stability and low drug leakage of polymer nanoparticles with low toxicity and capability of large-scale production of liposome and emulsion, which is an innovation in cucurbitacin solid lipid nanoparticle preparation and has enormous economical and social benefits.

A dripping pill of cucurbitacin for treating chronic metastatic hepatitis features high natural level and safety and low toxic by-effect. Its preparing process is also disclosed.

The invention relates to a transdermal administration composite containing cucurbitacin-type active ingredient. The transdermal transparent accelerator in the transdermal administration preparation of the cucurbitacin-type active ingredient is one or more composites of oleic acid, azone, eucalyptus oil, or isopropyl myristate and the like, and the dosage of the transdermal transparent accelerator is 0.1 to 50%, and 0.3 to 30% is preferred. The transdermal administration of cucurbitacin-type active ingredient can adopt liquid or semisolid preparation of gels, emulsion, ointment, solution agent, micro-emulsion, ethosomes or nebula and the like, or emplastrum such as patch, cataplasma and the like. After the transdermal administration of the preparations, the active ingredient can be absorbed by skin continuously and enter into human body to play a therapeutic role for a long while, the patient adaptability is significantly better than oral administration medication, therefore, the transdermal administration composite can be used for preventing and curing of hepatitis, cancer and other diseases and improving quality life of patients.

The invention provides a total cucurbitacin phosphatidyl cholate mixed micelle oral quick-absorption membrane and a preparation method thereof, and belongs to the technical field of traditional Chinese medicinal preparations and preparation methods thereof. The preparation method comprises the following steps: preparing a lipid membrane from phospholipid; dissolving cholate into a phosphate buffer solution to prepare a cholate liquid; performing ultrasonic mixing on the lipid membrane and the cholate liquid in a water bath to obtain a phosphatidyl cholate blank micelle liquid; adding total cucurbitacin powder into the phosphatidyl cholate blank micelle liquid to obtain phosphatidyl cholate mixed micelle of total cucurbitacin; sequentially adding hydroxypropyl methyl cellulose, low substituted hydroxyprepyl cellulose, microcrystalline cellulose and PEG400 (polyethylene glycol 400) into the phosphatidyl cholate mixed micelle of total cucurbitacin to obtain the total cucurbitacin phosphatidyl cholate mixed micelle oral quick-absorption membrane. The oral quick-absorption membrane has the advantages of improving the solubility of total cucurbitacin, increasing adhesive and penetrating effect of the oral quick-absorption membrane to oral mucosa, avoiding irritation of total cucurbitacin to gastrointestinal tracts, remarkably improving the bioavailability of total cucurbitacin and reducing adverse response.

A pure cucurbitacin product is obtained through conducting grinding, petroleum ether leaching and filtering on siraitia grosvenorii roots, adsorbing by resin after reduced pressure concentration on filtrate, eluting by different concentrations of eluents, decoloring the eluents, crystallizing and recrystallizing, and starch is obtained by jordaning filter residue, filtering to obtain starch milk, precipitating the starch milk through centrifugal separation, and drying or dehydrating 95% of ethanol. The cucurbitacin substances and the starch substances can be obtained at the same time by the method, so that the utilization rate of the siraitia grosvenorii roots is improved greatly, the starch resource is saved, the operation is simple, the residual of cucurbitacins in the starch in siraitia grosvenorii roots is reduced greatly, and the use scope of starch is expanded.

The invention provides a cucurbitacin medicinal composition and pharmaceutical application thereof. The cucurbitacin medicinal composition comprises cucurbitacin, a solubilizer, an antioxidant and a pH regulator, wherein the using amount of the pH regulator is enough for regulating the pH value of the medicinal composition to 3.5-7.5; the weight ratio of the cucurbitacin to the solubilizer is (1:600)-(1:3,150). The medicinal composition can be used for preparing medicaments for lowering the toxicity of cucurbitacin as well as anti-hepatitis, jaundice-removing and anti-cancer medicaments.

The invention discloses a nutritional pet feed which comprises the following raw materials by mass: 4-7 parts of animal proteins, 12-16 parts of plant proteins, 12-15 parts of plant fibers, 1-2 parts of salt, 4-6 parts of animal fat, 10-15 parts of corn starch, 25-30 parts of wheat flour, 1-2 parts of shrimp shell meal, 15-25 parts of wheat gluten, 40-45 parts of potato powder, 25-30 parts of gelatin, 3-4 parts of lycopene, 12-15 parts of glycerol, 3-4 parts of edible oil, 1-5 parts of threonine, 5-10 parts of egg white powder, 1-2 parts of dried orange peel powder, 2-3 parts of lysine, 10-30 parts of flour, 8-9 parts of lysine, 20-30 parts of corn flour, 10-30 parts of bean cakes, 3-5 parts of dried shrimps, 5-10 parts of bone powder, 15-20 parts of potato powder, 2-3 parts of yeasts, 2-3 parts of vitamin and 1-2 parts of cucurbitacin. The nutritional pet feed provided by the invention is rich in nutrition and easy to digest.

The invention belongs to the technical field of medicines, and discloses application of cucurbitacin in the preparation of medicaments for treating cough. The cucurbitacin comprises cucurbitacin A, B, C, D, E, I, Q and S, dihydrocucurbitacin A, B, C, D, E, I, Q and S, isocucurbitacin A, B, C, D, E, I, Q and S, and one or more than two of glucoside substances corresponding to each cucurbitacin. The cucurbitacin can be prepared into tablets, capsules, granules, powder, suspensions, syrups, oral liquid, patch, ointment, aerosol, suppository, nose drops or injection and the like with a pharmaceutically-acceptable carrier, can be used for treating the cough caused by various reasons, and has the effect of eliminating phlegm. The dose of healthy adults is between 0.1 and 5 mg/d, and preferable is between 0.3 and 3 mg/d; and the dose of children is subjected to discretionary reduction.

The invention relates to a pharmaceutical composition for treating liver cancer, which is prepared by proportionally mixing crude drugs including peimine, oroxin A, cucurbitacin and justicidin A. The pharmaceutical composition can be prepared in various forms according to conventional preparation technologies. The pharmaceutical composition provided by the invention is of great significance in preparation of drugs for treating liver cancer.

The invention relates to a pharmaceutical composition for treating AIDS. The pharmaceutical composition is prepared from raw materials of amentoflavone, cucurbitacin, peimine and protostemonine in certain proportion; and the pharmaceutical composition can be prepared into various dosage forms according to the conventional preparation process. The pharmaceutical composition provided by the invention has great significance to the preparation of medicaments for the treatment of AIDS.